Dosage

This information is provided for laboratory and research reference purposes only. PremoPeptides does not provide medical advice, and nothing on this page should be interpreted as a recommendation for human use. All products are sold strictly for research use and are not intended for human or animal consumption.
Retatrutide +
Research Summary A triple receptor agonist peptide acting on GLP-1, GIP, and glucagon receptors. Studied in metabolic research for its effects on energy expenditure and glucose regulation pathways. Dosing & Reconstitution by Dosage
10mg

Standard / Gradual Approach (1 mL = ~10.0 mg/mL)

Phase Weekly Dose Units (per injection) (mL) Vials Needed
Weeks 1–4 2 mg (2000 mcg) 20 units (0.20 mL) 1 vial per dose
Weeks 5–8 4 mg (4000 mcg) 40 units (0.40 mL) 1 vial per dose
Weeks 9–12 6 mg (6000 mcg) 60 units (0.60 mL) 1 vial per dose
Weeks 13+ 8 mg (8000 mcg) 80 units (0.80 mL) 1 vial per dose

Frequency: Inject once weekly subcutaneously[1][2]. All doses ≤10 mg can be drawn from one reconstituted 10 mg vial with 1.0 mL reconstitution. Volumes >1.0 mL may be split into 2 separate subcutaneous injections at different sites to ensure proper absorption[5].

Reconstitution Steps

  1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 4 weeks of reconstitution[16].
15mg Dosing & reconstitution guide for this dosage — add separately
20mg

Standard / Gradual Approach (2 mL = ~10.0 mg/mL)

Phase Weekly Dose Units (per injection) (mL) Vials Needed
Weeks 1–4 2 mg (2000 mcg) 20 units (0.20 mL) 1 vial per dose
Weeks 5–8 4 mg (4000 mcg) 40 units (0.40 mL) 1 vial per dose
Weeks 9–12 6 mg (6000 mcg) 60 units (0.60 mL) 1 vial per dose
Weeks 13+ 8 mg (8000 mcg) 80 units (0.80 mL) 1 vial per dose

Frequency: Inject once weekly subcutaneously[1][2]. All doses ≤12 mg can be drawn from one reconstituted 20 mg vial with 2.0 mL reconstitution. Volumes >1.0 mL may be split into 2 separate subcutaneous injections at different sites to ensure proper absorption[5].

Reconstitution Steps

  1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 4 weeks of reconstitution[16].
30mg

Standard / Gradual Approach (3 mL = ~10.0 mg/mL)

Phase Weekly Dose Units (per injection) (mL) Vials Needed
Weeks 1–4 2 mg (2000 mcg) 20 units (0.20 mL) 1 vial per dose
Weeks 5–8 4 mg (4000 mcg) 40 units (0.40 mL) 1 vial per dose
Weeks 9–12 6 mg (6000 mcg) 60 units (0.60 mL) 1 vial per dose
Weeks 13+ 8 mg (8000 mcg) 80 units (0.80 mL) 1 vial per dose

Frequency: Inject once weekly subcutaneously[1][2]. All doses ≤12 mg can be drawn from one reconstituted 30 mg vial, making this an efficient vial size for complete protocols. Volumes >1.0 mL may be split into 2 separate subcutaneous injections at different sites to ensure proper absorption[5].

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 4 weeks of reconstitution[16].
Tirzepatide +
Research Summary A dual GIP/GLP-1 receptor agonist peptide. Widely studied in metabolic research for its role in glucose homeostasis and incretin receptor signaling. Dosing & Reconstitution by Dosage
5mg

Standard / Gradual Approach (2 mL = 2.5 mg/mL)

Phase Weekly Dose (mg) Units (per injection) (mL)
Weeks 1–4 2.5 mg 100 units (1.0 mL) × 1 injection
Weeks 5–8 5 mg 100 units (1.0 mL) × 2 injections
Weeks 9–12 7.5 mg 100 units (1.0 mL) × 3 injections
Weeks 13–16 10 mg 100 units (1.0 mL) × 4 injections

Frequency: Inject once weekly subcutaneously on the same day each week[1][5]. For doses requiring multiple injections, administer consecutively at different sites. Dose increases occur every 4 weeks to minimize gastrointestinal side effects[1]. Higher doses (12.5–15 mg/week) may be used in subsequent phases if tolerated and clinically indicated.

Reconstitution Steps

  1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 28 days of reconstitution[6].
10mg

Standard / Gradual Approach (2 mL = 5.0 mg/mL)

Phase Weekly Dose (mg) Units (per injection) (mL)
Weeks 1–4 2.5 mg 50 units (0.50 mL) × 1 injection
Weeks 5–8 5 mg 100 units (1.0 mL) × 1 injection
Weeks 9–12 7.5 mg 75 units (0.75 mL) × 2 injections
Weeks 13–16 10 mg 100 units (1.0 mL) × 2 injections

Frequency: Inject once weekly subcutaneously on the same day each week[1][5]. For doses requiring multiple injections, administer consecutively at different sites. Dose increases occur every 4 weeks to minimize gastrointestinal side effects[1]. Higher doses (12.5–15 mg/week) may be used in subsequent phases if tolerated and clinically indicated.

Reconstitution Steps

  1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 28 days of reconstitution[6].
15mg

Standard / Gradual Approach (2 mL = 7.5 mg/mL)

Phase Weekly Dose (mg) Units (per injection) (mL)
Weeks 1–4 2.5 mg 33 units (0.33 mL) × 1 injection
Weeks 5–8 5 mg 67 units (0.67 mL) × 1 injection
Weeks 9–12 7.5 mg 100 units (1.0 mL) × 1 injection
Weeks 13–16 10 mg 67 units (0.67 mL) × 2 injections

Frequency: Inject once weekly subcutaneously on the same day each week[1][5]. For doses requiring multiple injections, administer consecutively at different sites. Dose increases occur every 4 weeks to minimize gastrointestinal side effects[1]. Higher doses (12.5–15 mg/week) may be used in subsequent phases if tolerated and clinically indicated.

Reconstitution Steps

  1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 28 days of reconstitution[6].
20mg Dosing & reconstitution guide for this dosage — add separately
30mg

Standard / Gradual Approach (3 mL = 10.0 mg/mL)

Phase Weekly Dose (mg) Units (per injection) (mL)
Weeks 1–4 2.5 mg 25 units (0.25 mL) × 1 injection
Weeks 5–8 5 mg 50 units (0.50 mL) × 1 injection
Weeks 9–12 7.5 mg 75 units (0.75 mL) × 1 injection
Weeks 13–16 10 mg 100 units (1.0 mL) × 1 injection

Frequency: Inject once weekly subcutaneously on the same day each week[1][5]. All doses fit in a single 1 mL insulin syringe at this concentration. Dose increases occur every 4 weeks to minimize gastrointestinal side effects[1]. Higher doses (12.5–15 mg/week) may be used in subsequent phases if tolerated and clinically indicated.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 28 days of reconstitution[6].
40mg Dosing & reconstitution guide for this dosage — add separately
Semaglutide +
Research Summary A GLP-1 receptor agonist peptide extensively studied in metabolic and endocrine research for its effects on glucose regulation and appetite-related signaling pathways. Dosing & Reconstitution by Dosage
5mg

Standard / Gradual Titration (2 mL = ~2.5 mg/mL)

Week Weekly Dose Units (per injection) (mL)
Weeks 1–4 250 mcg (0.25 mg) 10 units (0.10 mL)
Weeks 5–8 500 mcg (0.5 mg) 20 units (0.20 mL)
Weeks 9–12 1000 mcg (1.0 mg) 40 units (0.40 mL)
Weeks 13–16 1700 mcg (1.7 mg) 68 units (0.68 mL)
Weeks 17+ (Maintenance) 2400 mcg (2.4 mg) 96 units (0.96 mL)

Frequency: Inject once weekly subcutaneously. This gradual titration protocol improves tolerability and is consistent with FDA-approved dosing strategies for weight management[1][3]. Administer on the same day each week at any time, with or without meals. Note: We use 2.0 mL reconstitution (instead of 3.0 mL) to keep the highest maintenance dose under 1.0 mL per injection.

Reconstitution Steps

  1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall to minimize foaming; avoid shaking.
  3. Gently swirl or roll the vial until the powder is fully dissolved.
  4. Label the vial with the reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use reconstituted solution within 28 days for maximum potency and safety[8].
10mg

Standard / Gradual Titration (3 mL = ~3.33 mg/mL)

Week Weekly Dose Units (per injection) (mL)
Weeks 1–4 250 mcg (0.25 mg) 7.5 units (0.075 mL)
Weeks 5–8 500 mcg (0.5 mg) 15 units (0.15 mL)
Weeks 9–12 1000 mcg (1.0 mg) 30 units (0.30 mL)
Weeks 13–16 1700 mcg (1.7 mg) 51 units (0.51 mL)
Weeks 17+ (Maintenance) 2400 mcg (2.4 mg) 72 units (0.72 mL)

Frequency: Inject once weekly subcutaneously. This gradual titration protocol improves tolerability and is consistent with FDA-approved dosing strategies for weight management[1][3]. Administer on the same day each week at any time, with or without meals.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall to minimize foaming; avoid shaking.
  3. Gently swirl or roll the vial until the powder is fully dissolved.
  4. Label the vial with the reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use reconstituted solution within 28 days for maximum potency and safety[8].

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

20mg

Standard / Gradual Titration (3 mL = ~6.67 mg/mL)

Week Weekly Dose Units (per injection) (mL)
Weeks 1–4 250 mcg (0.25 mg) 4 units (0.04 mL)
Weeks 5–8 500 mcg (0.5 mg) 7.5 units (0.075 mL)
Weeks 9–12 1000 mcg (1.0 mg) 15 units (0.15 mL)
Weeks 13–16 1700 mcg (1.7 mg) 25.5 units (0.255 mL)
Weeks 17+ (Maintenance) 2400 mcg (2.4 mg) 36 units (0.36 mL)

Frequency: Inject once weekly subcutaneously. This gradual titration protocol improves tolerability and is consistent with FDA-approved dosing strategies for weight management[1][3]. Administer on the same day each week at any time, with or without meals.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall to minimize foaming; avoid shaking.
  3. Gently swirl or roll the vial until the powder is fully dissolved.
  4. Label the vial with the reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use reconstituted solution within 28 days for maximum potency and safety[8].
30mg Dosing & reconstitution guide for this dosage — add separately
Melanotan 2 +
Research Summary A synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Studied in research models for melanocortin receptor activity and pigmentation pathways. Dosing & Reconstitution by Dosage
10mg

Standard / Gradual Titration (3 mL = 3.33 mg/mL)

Week / Phase Daily Dose Units (per injection) (mL)
Week 1 250 mcg (0.25 mg) 7.5 units (0.075 mL)
Week 2 500 mcg (0.5 mg) 15 units (0.15 mL)
Week 3 750 mcg (0.75 mg) 22.5 units (0.225 mL)
Weeks 4–8 1000 mcg (1 mg) 30 units (0.30 mL)
Maintenance (after Week 8) 500–1000 mcg (1–2× weekly) 15–30 units (0.15–0.30 mL)

Frequency: Inject once daily subcutaneously during the initial 8-week tanning phase; transition to 1–2 injections per week for maintenance dosing to sustain pigmentation[3]. This schedule uses the standard 3.0 mL dilution for consistent unit measurements. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall to avoid foaming; do not shake vigorously.
  3. Gently roll or swirl the vial until the powder is fully dissolved.
  4. Label the vial with the reconstitution date and store refrigerated at 2–8 °C (35.6–46.4 °F), protected from light.
GHK-Cu +
Research Summary A naturally occurring copper-binding tripeptide. Studied in tissue research for its role in collagen synthesis and extracellular matrix remodeling. Dosing & Reconstitution by Dosage
50mg

Standard / Conservative Approach (3 mL = 16.67 mg/mL; 5 days/week)

Week/Phase Dose per Injection Units (per injection) (mL)
Weeks 1-4 1.0 mg (1000 mcg) 6 units (0.06 mL)
Weeks 5-8 1.5 mg (1500 mcg) 9 units (0.09 mL)
Weeks 9-12+ 2.0 mg (2000 mcg) 12 units (0.12 mL)

Frequency: Once daily, 5 days per week, progressing from 1.0 mg to 1.5 mg and then 2.0 mg as shown above. At 16.67 mg/mL, those doses equal 6, 9, and 12 U-100 units[18]. Use a U-100 syringe with markings that clearly display every value in the table.

Reconstitution Steps

  1. Draw 3.0 mL of the protocol-specified sterile diluent with a sterile syringe.
  2. Add it slowly down the vial wall to reduce foaming.
  3. Gently swirl or roll until dissolved. Do not shake.
  4. Label the vial with the 16.67 mg/mL concentration, preparation date, and storage instructions.
100mg

Standard / Conservative Approach (3 mL = 33.33 mg/mL; 5 days/week)

Week/Phase Dose per Injection Units (per injection) (mL)
Weeks 1-4 1.0 mg (1000 mcg) 3 units (0.03 mL)
Weeks 5-8 1.5 mg (1500 mcg) 4.5 units (0.045 mL)
Weeks 9-12+ 2.0 mg (2000 mcg) 6 units (0.06 mL)

Frequency: Once daily, 5 days per week, progressing from 1.0 mg to 1.5 mg and then 2.0 mg as shown above. At 33.33 mg/mL, those doses equal 3, 4.5, and 6 U-100 units[18]. Use a U-100 syringe with markings that clearly display every value in the table.

Reconstitution Steps

  1. Draw 3.0 mL of the protocol-specified sterile diluent with a sterile syringe.
  2. Add it slowly down the vial wall to reduce foaming.
  3. Gently swirl or roll until dissolved. Do not shake.
  4. Label the vial with the 33.33 mg/mL concentration, preparation date, and storage instructions.
GLOW +
Research Summary A combination peptide blend (GHK-Cu, BPC-157, TB-500) studied in tissue repair and regenerative research models. Dosing & Reconstitution by Dosage
70mg

Standard Approach (3 mL = 23.3 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–4 2,330 mcg 10 units (0.10 mL)

Frequency: Inject once daily subcutaneously. This schedule maintains a consistent dose throughout the 4-week cycle, delivering approximately 1.7 mg GHK-Cu, 0.33 mg TB-500, and 0.33 mg BPC-157 per injection. This once-daily regimen aligns with common research protocols for BPC-157 and similar repair peptides[5][6]. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall to minimize foaming.
  3. Gently swirl or roll the vial until fully dissolved (do not shake vigorously).
  4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 4 weeks for optimal potency and safety.
KLOW +
Research Summary A combination peptide blend (GHK-Cu, BPC-157, TB-500, KPV) studied in tissue repair research, with KPV specifically studied for anti-inflammatory signaling pathways. Dosing & Reconstitution by Dosage
80mg

Standard / Gradual Approach (3 mL = ~26.7 mg/mL Total)

This multi-peptide blend provides synergistic regenerative, anti-inflammatory, and tissue-repair support. The following titration schedule allows gradual introduction of each component.

Week Daily Dose (per component) Units (per injection) (mL)
Weeks 1–2 TB-500: 250 mcg | BPC-157: 250 mcg | KPV: 250 mcg | GHK-Cu: 1.25 mg 7.5 units (0.075 mL)
Weeks 3–4 TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg 15 units (0.15 mL)
Weeks 5–8 TB-500: 750 mcg | BPC-157: 750 mcg | KPV: 750 mcg | GHK-Cu: 3.75 mg 22.5 units (0.225 mL)
Weeks 9–12 (Maintenance) TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg 15 units (0.15 mL)

Frequency: Inject once daily subcutaneously. This schedule uses a 3.0 mL dilution to maintain measurable volumes. For ≤10-unit (≤0.10 mL) administrations during initial weeks, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Syringe Math Reference

With 3.0 mL reconstitution volume and 80 mg total peptide:

Total concentration: 26.67 mg/mL (26,667 mcg/mL)
TB-500: 3.33 mg/mL → 33.3 mcg per unit
BPC-157: 3.33 mg/mL → 33.3 mcg per unit
KPV: 3.33 mg/mL → 33.3 mcg per unit
GHK-Cu: 16.67 mg/mL → 166.7 mcg per unit
1 unit (0.01 mL) = 33.3 mcg each of TB-500, BPC-157, KPV + 166.7 mcg GHK-Cu

BPC-157 +
Research Summary A stable pentadecapeptide derived from a partial sequence of body protection compound. Widely studied in animal models for gastrointestinal and musculoskeletal tissue repair research. Dosing & Reconstitution by Dosage
5mg

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

Route: Subcutaneous | Frequency: Once daily

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 200 mcg (0.2 mg) 12 units (0.12 mL)
Weeks 3–4 400 mcg (0.4 mg) 24 units (0.24 mL)
Weeks 5–8+ 600 mcg (0.6 mg) 36 units (0.36 mL)

Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per-injection units well above 10 for better accuracy. Dosing is extrapolated from preclinical models[1][6]; human clinical validation remains limited.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
10mg

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 200 mcg (0.2 mg) 6 units (0.06 mL)
Weeks 3–4 400 mcg (0.4 mg) 12 units (0.12 mL)
Weeks 5–8+ 600 mcg (0.6 mg) 18 units (0.18 mL)

Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per-injection units well above 5 for better accuracy. Dosing is extrapolated from preclinical models[1][6]; human clinical validation remains limited.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
TB-500 +
Research Summary A synthetic peptide fragment of Thymosin Beta-4. Studied in tissue research for its role in actin regulation, cell migration, and wound-healing pathways. Dosing & Reconstitution by Dosage
5mg

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

Phase Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 500 mcg 30 units (0.30 mL)
Weeks 3–4 600 mcg 36 units (0.36 mL)
Weeks 5–8 750 mcg 45 units (0.45 mL)
Weeks 9–12 1000 mcg 60 units (0.60 mL)

Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units ≥30 for excellent accuracy. Total weekly dose averages ~5 mg, consistent with research protocols[3][4].

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label with date and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
10mg

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Phase Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 500 mcg 15 units (0.15 mL)
Weeks 3–4 600 mcg 18 units (0.18 mL)
Weeks 5–8 750 mcg 23 units (0.23 mL)
Weeks 9–12 1000 mcg 30 units (0.30 mL)

Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units in a comfortable range for accurate measurement. Total weekly dose averages ~5 mg, consistent with research protocols[3][4].

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label with date and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
20mg

Standard / Gradual Approach (3 mL = ~6.67 mg/mL)

Phase Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 1000 mcg 15 units (0.15 mL)
Weeks 3–4 1200 mcg 18 units (0.18 mL)
Weeks 5–8 1500 mcg 23 units (0.23 mL)
Weeks 9–12 2000 mcg 30 units (0.30 mL)

Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units in a comfortable range for accurate measurement. Total weekly dose averages ~10 mg, consistent with research protocols[3][4].

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label with date and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
MOTS-c +
Research Summary A mitochondrial-derived peptide encoded within mitochondrial DNA. Studied in metabolic research for its role in mitochondrial function and cellular energy regulation. Dosing & Reconstitution by Dosage
10mg

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 200 mcg (0.2 mg) 6 units (0.06 mL)
Weeks 3–4 400 mcg (0.4 mg) 12 units (0.12 mL)
Weeks 5–6 600 mcg (0.6 mg) 18 units (0.18 mL)
Weeks 7–8 800 mcg (0.8 mg) 24 units (0.24 mL)
Weeks 9–10+ 1,000 mcg (1.0 mg) 30 units (0.30 mL)

Frequency: Inject once daily subcutaneously[7]. This schedule uses the largest practical dilution (3.0 mL) to maintain per‑injection accuracy. Stay at each dose level for approximately 2 weeks before increasing, and monitor for any adverse reactions[7].

For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake vigorously).
  4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 7 days for optimal potency[7].
40mg

Standard / Gradual Approach (3 mL = ~13.33 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 200 mcg (0.2 mg) 1.5 units (0.015 mL)
Weeks 3–4 400 mcg (0.4 mg) 3 units (0.03 mL)
Weeks 5–6 600 mcg (0.6 mg) 4.5 units (0.045 mL)
Weeks 7–8 800 mcg (0.8 mg) 6 units (0.06 mL)
Weeks 9–10+ 1,000 mcg (1.0 mg) 7.5 units (0.075 mL)

Frequency: Inject once daily subcutaneously[7]. Stay at each dose level for approximately 2 weeks before increasing, and monitor for any adverse reactions[7].

For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake vigorously).
  4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 7 days for optimal potency[7].
NAD+ +
Research Summary A coenzyme central to cellular energy metabolism and redox reactions. Studied in aging and mitochondrial research for its role in cellular energy production. Dosing & Reconstitution by Dosage
500mg

Standard / Gradual Titration Approach (3 mL = 166.7 mg/mL)

Week Daily Dose (mg) Units (per injection) (mL)
Week 1 50 mg 30 units (0.30 mL)
Week 2 75 mg 45 units (0.45 mL)
Weeks 3–8 100 mg 60 units (0.60 mL)
Weeks 9–12 100 mg 60 units (0.60 mL)
Weeks 13–16 100 mg 60 units (0.60 mL)

Frequency: Inject once daily subcutaneously. This gradual titration protocol begins at 50 mg daily to assess tolerance, as starting too high can produce adverse reactions such as insomnia, anxiety, or fatigue[4]. Most individuals find doses in the 50–100 mg range well‑tolerated after ramp‑up[5]. The 3.0 mL dilution keeps per‑injection volumes practical and allows for accurate unit measurements on standard insulin syringes.

Reconstitution Steps

  1. Allow the lyophilized vial to reach room temperature before opening to minimize moisture condensation.
  2. Draw 3.0 mL bacteriostatic water (0.9% benzyl alcohol) with a sterile syringe.
  3. Inject slowly down the vial wall to avoid foaming; do not aim directly at the powder.
  4. Gently swirl or roll the vial until the powder fully dissolves (do not shake vigorously). The resulting solution should be clear and colorless. If discoloration or precipitate appears, discard.
  5. Label with the reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 14 days; inspect before each use for clarity.

Note: Each 0.01 mL (1 unit) contains approximately 1.67 mg of NAD+. Example conversions: 50 mg = 30 units; 75 mg = 45 units; 100 mg = 60 units.

1000mg

Standard / Gradual Titration Approach (3 mL = 333.3 mg/mL)

Week Daily Dose (mg) Units (per injection) (mL)
Week 1 50 mg 15 units (0.15 mL)
Week 2 75 mg 22.5 units (0.225 mL)
Weeks 3–8 100 mg 30 units (0.30 mL)
Weeks 9–12 100 mg 30 units (0.30 mL)
Weeks 13–16 100 mg 30 units (0.30 mL)

Frequency: Inject once daily subcutaneously. This gradual titration protocol begins at 50 mg daily to assess tolerance, as starting too high can produce adverse reactions such as insomnia, anxiety, or fatigue[4]. Most individuals find doses in the 50–100 mg range well‑tolerated after ramp‑up[5]. The 3.0 mL dilution keeps per‑injection volumes practical and allows for accurate unit measurements on standard insulin syringes.

Reconstitution Steps

  1. Allow the lyophilized vial to reach room temperature before opening to minimize moisture condensation.
  2. Draw 3.0 mL bacteriostatic water (0.9% benzyl alcohol) with a sterile syringe.
  3. Inject slowly down the vial wall to avoid foaming; do not aim directly at the powder.
  4. Gently swirl or roll the vial until the powder fully dissolves (do not shake vigorously). The resulting solution should be clear and colorless. If discoloration or precipitate appears, discard.
  5. Label with the reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 14 days; inspect before each use for clarity.

Note: Each 0.01 mL (1 unit) contains approximately 3.33 mg of NAD+. Example conversions: 50 mg = 15 units; 75 mg = 22.5 units; 100 mg = 30 units.

IGF1-LR3 +
Research Summary A long-acting analog of insulin-like growth factor 1 (IGF-1) with reduced binding protein affinity. Studied in cell growth and proliferation research. Dosing & Reconstitution by Dosage
1mg

Standard / Gradual Approach (3 mL = ~0.333 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 20 mcg (0.02 mg) 6 units (0.06 mL)
Weeks 3–4 40 mcg (0.04 mg) 12 units (0.12 mL)
Weeks 5–8 50 mcg (0.05 mg) 15 units (0.15 mL)

Frequency: Inject once daily subcutaneously, typically in the morning or post-workout with food intake to mitigate insulin-like effects on blood glucose[3]. This schedule uses the maximum practical dilution (3.0 mL) for clear measurements. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall to avoid foaming; do not shake.
  3. Gently swirl or roll until the lyophilized powder dissolves completely into a clear solution.
  4. Label the vial with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 30 days of reconstitution; for longer storage, prepare aliquots and freeze at −20 °C (−4 °F) for up to 3–6 months[4].
SS-31 +
Research Summary A mitochondria-targeted peptide (elamipretide) studied for its interaction with cardiolipin and its role in oxidative stress research. Dosing & Reconstitution by Dosage
10mg

Standard / Gradual Approach (1 mL = 10 mg/mL)

Week Daily Dose (mg) Units (per injection) (mL)
Weeks 1–2 5 mg (5000 mcg) 50 units (0.50 mL)
Weeks 3–8 10 mg (10,000 mcg) 100 units (1.0 mL)

Frequency: Inject once daily subcutaneously at a consistent time. This concentrated dilution (1.0 mL per 10 mg vial) keeps standard doses within a single insulin syringe for convenience and accuracy.

Reconstitution Steps

  1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid vigorous shaking to prevent foaming.
  3. Gently swirl/roll until fully dissolved (clear solution).
  4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 4 weeks.
Tesamorelin +
Research Summary A synthetic analog of growth hormone-releasing hormone (GHRH). Studied in endocrine research for its role in growth hormone secretion pathways. Dosing & Reconstitution by Dosage
5mg

Standard FDA-Approved Protocol (2.5 mL = 2.0 mg/mL)

Week Daily Dose (mg / mcg) Units (per injection) (mL)
Week 1 1 mg / 1000 mcg 50 units (0.50 mL)
Weeks 2–12+ 2 mg / 2000 mcg 100 units (1.00 mL)

Frequency: Inject once daily subcutaneously, preferably in the evening to coincide with nocturnal GH release[5][6]. The 2 mg daily dose is the standard FDA-approved regimen for HIV lipodystrophy[7][8]. A one-week titration at 1 mg may improve tolerability before advancing to the full 2 mg dose.

Reconstitution Steps

  1. Draw 2.5 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 7 days when reconstituted with bacteriostatic water[1].
10mg

Standard FDA-Approved Protocol (3.0 mL = ~3.33 mg/mL)

Week Daily Dose (mg / mcg) Units (per injection) (mL)
Week 1 1 mg / 1000 mcg 30 units (0.30 mL)
Weeks 2–12+ 2 mg / 2000 mcg 60 units (0.60 mL)

Frequency: Inject once daily subcutaneously, preferably in the evening to coincide with nocturnal GH release[5][6]. The 2 mg daily dose is the standard FDA-approved regimen for HIV lipodystrophy[7][8]. A one-week titration at 1 mg may improve tolerability before advancing to the full 2 mg dose.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 7 days when reconstituted with bacteriostatic water[1].
Sermorelin +
Research Summary A synthetic fragment of growth hormone-releasing hormone (GHRH). Studied in research models examining growth hormone secretion and pituitary signaling. Dosing & Reconstitution by Dosage
10mg

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week Daily Dose (µg) Units (per injection) (mL)
Weeks 1–2 200 µg (0.2 mg) 6 units (0.06 mL)
Weeks 3–4 300 µg (0.3 mg) 9 units (0.09 mL)
Weeks 5–6 400 µg (0.4 mg) 12 units (0.12 mL)
Weeks 7–8 500 µg (0.5 mg) 15 units (0.15 mL)

Frequency: Inject once daily subcutaneously at bedtime. Bedtime administration is strongly recommended because endogenous GH secretion peaks during sleep[3]. This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units measurable with standard insulin syringes.

For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; gently swirl to dissolve (do not shake vigorously)[2].
  3. Label with reconstitution date and refrigerate at 2–8 °C (36–46 °F), protected from light[2][4].
  4. Wipe vial stopper with alcohol before each use; use a new sterile needle and syringe for each injection[2].
Ipamorelin +
Research Summary A selective growth hormone secretagogue peptide. Studied in research for its targeted effect on growth hormone release with minimal impact on other hormones. Dosing & Reconstitution by Dosage
10mg

Standard / Gradual Approach (3.0 mL = ~3.33 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 100 mcg 3 units (0.03 mL)
Weeks 3–4 150 mcg 5 units (0.05 mL)
Weeks 5–8 200 mcg 6 units (0.06 mL)
Weeks 9–12 250 mcg 8 units (0.08 mL)

Frequency: Inject once daily subcutaneously, ideally 30–60 minutes before bedtime on an empty stomach to synergize with natural nocturnal GH secretion[4][5]. For doses ≤10 units (≤0.10 mL), consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake vigorously).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Semax +
Research Summary A synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH). Studied in neurological research models for neurotrophic signaling pathways. Dosing & Reconstitution by Dosage
10mg

Semax 10 mg Nasal Spray Calculations

Both options begin with 3.0 mL in the peptide vial. Transfer the complete solution, then add enough vehicle to reach the measured final volume.

Measured Final Volume Vehicle Added After Transfer Final Concentration Per Verified 0.10 mL Spray
5.0 mL About 2.0 mL 2,000 mcg/mL 200 mcg
50 nominal sprays
10.0 mL About 7.0 mL 1,000 mcg/mL 100 mcg
100 nominal sprays

Calculation basis: Each row uses the full 10 mg vial and a pump verified to release 0.10 mL per complete actuation. Nominal spray counts are calculated before priming and normal residual hold-up.

How to Prepare the 5 mL or 10 mL Research Bottle

  1. Confirm the 10 mg vial, selected sterile research vehicle, actuator bottle capacity, and documented pump output.
  2. Add 3.0 mL of compatible sterile vehicle to the vial with aseptic transfer technique.
  3. Gently swirl until the contents are dissolved. Do not shake.
  4. Transfer the complete 3.0 mL solution into a sterile 5 mL or 10 mL nasal actuator bottle.
  5. Add enough vehicle to reach a measured final volume of exactly 5.0 mL or 10.0 mL. The theoretical additions are approximately 2.0 mL and 7.0 mL.
  6. Secure the pump and label the bottle with the peptide amount, final volume, concentration, pump output, and preparation date.
  7. Prime the pump according to the actuator instructions and record the priming sprays in the research log.

Vehicle context: The worked example can use sterile 0.9% saline as a research vehicle. Kaplan and colleagues reported physiological solution in one human experiment. The registered 0.1% Semax product used purified water with methylparaben, so the saline example is not the same as the registered multidose formulation[1][4].

Research Amount to Spray Equivalents

Research Amount 5 mL Option (200 mcg per Spray) 10 mL Option (100 mcg per Spray)
200 mcg 1 spray 2 sprays
300 mcg 1.5 theoretical sprays 3 sprays
400 mcg 2 sprays 4 sprays
500 mcg 2.5 theoretical sprays 5 sprays

These rows are concentration conversions. They do not turn one study amount into a universal schedule. Fractional results are mathematical only because a metered pump cannot deliver half of a full actuation.

Selank +
Research Summary A synthetic peptide analog of tuftsin. Studied in research models examining anxiolytic-related neural signaling pathways. Dosing & Reconstitution by Dosage
10mg

Selank 10 mg Nasal Spray Calculations

Both options begin with 3.0 mL in the peptide vial. Transfer the complete solution, then add enough vehicle to reach the measured final volume.

Measured Final Volume Vehicle Added After Transfer Final Concentration Per Verified 0.10 mL Spray
5.0 mL About 2.0 mL 2,000 mcg/mL 200 mcg
50 nominal sprays
10.0 mL About 7.0 mL 1,000 mcg/mL 100 mcg
100 nominal sprays

Calculation basis: Each row uses the full 10 mg vial and a pump verified to release 0.10 mL per complete actuation. Nominal spray counts are calculated before priming and normal residual hold-up.

How to Prepare the 5 mL or 10 mL Research Bottle

  1. Confirm the 10 mg vial, selected sterile research vehicle, actuator bottle capacity, and documented pump output.
  2. Add 3.0 mL of compatible sterile vehicle to the vial with aseptic transfer technique.
  3. Gently swirl until the contents are dissolved. Do not shake.
  4. Transfer the complete 3.0 mL solution into a sterile 5 mL or 10 mL nasal actuator bottle.
  5. Add enough vehicle to reach a measured final volume of exactly 5.0 mL or 10.0 mL. The theoretical additions are approximately 2.0 mL and 7.0 mL.
  6. Secure the pump and label the bottle with the peptide amount, final volume, concentration, pump output, and preparation date.
  7. Prime the pump according to the actuator instructions and record the priming sprays in the research log.

Vehicle context: The worked example can use sterile 0.9% saline as a research vehicle. The registered 0.15% Selank product contains 1.10 mg/mL Selank in purified water with methylparaben, so the saline example is not the same as the manufactured multidose drop formulation[5].

Mathematical Actuator Equivalents

Literature Amount 5 mL Option (200 mcg per Spray) 10 mL Option (100 mcg per Spray)
300 mcg 1.5 theoretical sprays 3 sprays
900 mcg 4.5 theoretical sprays 9 sprays
2,700 mcg 13.5 theoretical sprays 27 sprays

These rows are concentration conversions, not a universal schedule. Fractional results are mathematical only because a metered pump cannot deliver half of a full actuation. Amounts reported with a manufactured drop formulation should not be treated as direct generic-pump instructions.

CJC-1295 no DAC +
Research Summary A synthetic analog of growth hormone-releasing hormone (GHRH) without Drug Affinity Complex. Studied in research for its short-acting effect on growth hormone pulsatility. Dosing & Reconstitution by Dosage
5mg

Standard / Gradual Approach (2 mL = 2500 mcg/mL)

Week Per-Injection Dose (mcg) Units (per injection) (mL) Weekly Total
Weeks 1–2 300 mcg (0.3 mg) 12 units (0.12 mL) 600 mcg/week
Weeks 3–4 500 mcg (0.5 mg) 20 units (0.20 mL) 1000 mcg/week
Weeks 5–6 750 mcg (0.75 mg) 30 units (0.30 mL) 1500 mcg/week
Weeks 7–12 1000 mcg (1 mg) 40 units (0.40 mL) 2000 mcg/week

Frequency: Inject twice weekly subcutaneously (e.g., Monday/Thursday or Tuesday/Friday). The extended 6–8-day half-life from the DAC modification supports less frequent dosing compared to non-DAC GHRH analogs[1][2]. Once-weekly dosing is also studied; adjust frequency based on protocol requirements.

For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
PEG-MGF +
Research Summary A pegylated form of mechano growth factor, a splice variant of IGF-1. Studied in research models examining muscle satellite cell activation. Dosing & Reconstitution by Dosage
2mg

Standard / Gradual Approach (3 mL = ~0.667 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 200 mcg 30 units (0.30 mL)
Weeks 3–4 300 mcg 45 units (0.45 mL)
Weeks 5–6 400 mcg 60 units (0.60 mL)
Weeks 7–8 500 mcg 75 units (0.75 mL)

Frequency: Inject once daily subcutaneously. Pegylation extends MGF’s half-life, allowing systemic once-daily SC dosing instead of frequent intramuscular injections[7]. This schedule uses the largest practical dilution (3.0 mL) to keep per-injection volumes easy to measure accurately on standard insulin syringes.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
PT-141 +
Research Summary A synthetic peptide (bremelanotide) that acts on melanocortin receptors. Studied in research models examining central nervous system pathways related to arousal signaling. Dosing & Reconstitution by Dosage
10mg

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–8 500 mcg (0.5 mg) 15 units (0.15 mL)
Weeks 9–12 1000 mcg (1.0 mg) 30 units (0.30 mL)
Weeks 13–16 1500 mcg (1.5 mg) 45 units (0.45 mL)

Route & Frequency: Inject once daily subcutaneously (abdomen or thigh). The subcutaneous route provides approximately 100% bioavailability and is better tolerated than intranasal delivery[3]. The FDA-approved on-demand regimen uses 1.75 mg SC before intercourse (max 8 doses/month)[3]; however, daily protocols at 2.5 mg have been studied in obese women for appetite and weight reduction[4], suggesting daily use can be tolerated. This schedule uses a conservative titration starting below the FDA on-demand dose.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Epitalon +
Research Summary A synthetic tetrapeptide studied in aging research for its proposed role in telomerase activity and cellular senescence pathways. Dosing & Reconstitution by Dosage
10mg

Standard Protocol (2 mL = 5 mg/mL)

Phase Daily Dose (mcg) Units (per injection) (mL)
Days 1–20 (Cycle On) 5,000 mcg (5 mg) 100 units (1.00 mL)
Weeks 4–26 (Cycle Off) 0 mcg —

Frequency: Inject once daily subcutaneously, preferably in the evening or at bedtime to synergize with natural melatonin rhythms[3]. Complete 20 consecutive days, then observe a 4–6 month off-cycle before repeating (typically 2 cycles per year)[5].

Reconstitution Steps

  1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Glutathione +
Research Summary A tripeptide composed of glutamine, cysteine, and glycine, recognized as a key intracellular antioxidant. Studied in research on oxidative stress and cellular detoxification pathways. Dosing & Reconstitution by Dosage
600mg

Standard / Gradual Approach (2 mL = 300 mg/mL)

Week Daily Dose (mg) Units (per injection) (mL)
Weeks 1–2 100 mg 33 units (0.33 mL)
Weeks 3–4 150 mg 50 units (0.50 mL)
Weeks 5–8 200 mg 67 units (0.67 mL)

Frequency: Inject once daily subcutaneously, or split into every-other-day dosing based on protocol goals[5]. Some protocols utilize 200 mg 1–2 × weekly for maintenance[6]. This schedule uses a practical 2.0 mL dilution for accurate measurements with standard insulin syringes.

Reconstitution Steps

  1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Hexarelin +
Research Summary A potent synthetic growth hormone secretagogue peptide. Studied in research models examining growth hormone release and cardioprotective signaling pathways. Dosing & Reconstitution by Dosage
2mg Dosing & reconstitution guide for this dosage — add separately
Vitamin B12 (Injectable) +
Research Summary An essential cobalamin cofactor involved in cellular metabolism and neurological function. Studied in research models examining metabolic and neurological pathways. Dosing & Reconstitution by Dosage
50ml (5MG/ML) Dosing & reconstitution guide for this dosage — add separately
AOD-9604 +
Research Summary A modified fragment of the human growth hormone molecule. Studied in metabolic research for its role in lipid metabolism pathways. Dosing & Reconstitution by Dosage
5mg

Standard / Gradual Approach (3 mL = ~1.667 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–4 300 mcg 18 units (0.18 mL)
Weeks 5–12 500 mcg 30 units (0.30 mL)

Frequency: Inject once daily subcutaneously (typically in the morning on an empty stomach). This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units ≥10 for better accuracy. Rotate injection sites (abdomen, thighs, upper arms) to minimize local irritation.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
5-Amino-1MQ +
Research Summary A small molecule inhibitor of nicotinamide N-methyltransferase (NNMT). Studied in metabolic research examining adipocyte and cellular energy pathways. Dosing & Reconstitution by Dosage
10mg

Subcutaneous Protocol (2 mL = 5 mg/mL)

Phase Daily Dose (mg) Units (per injection) (mL)
Days 1–2 (Tolerance) 2.5 mg (2500 mcg) 50 units (0.50 mL)
Days 3+ (Standard) 5 mg (5000 mcg) 100 units (1.00 mL)
Alternative BID 2.5 mg twice daily 50 units (0.50 mL) × 2

Frequency: Inject once or twice daily subcutaneously. Due to the compound’s plasma half-life of approximately 3.8–6.9 hours[5], twice-daily (BID) dosing may provide more sustained NNMT inhibition. A single 10 mg vial provides 2–4 days of material at these doses.

Reconstitution Steps

  1. Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
  2. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  3. Inject slowly down the vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved—solution should be clear (do not shake).
  5. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2–4 weeks.
L-Carnitine +
Research Summary An amino acid derivative involved in the transport of fatty acids into mitochondria. Studied in research examining cellular energy metabolism pathways. Dosing & Reconstitution by Dosage
200MG/ML

Standard / Gradual Approach (2.0 mL = 100 mg/mL)

Week Daily Dose Units (per injection) (mL)
Weeks 1–2 50 mg 50 units (0.50 mL)
Weeks 3–8 100 mg 100 units (1.0 mL)
Weeks 9–12 100 mg 100 units (1.0 mL)

Frequency: Inject once daily subcutaneously. This 2.0 mL reconstitution provides optimal concentration for convenient dosing: 100 mg maintenance dose = exactly 1.0 mL (100 units)[8]. For advanced protocols requiring 150–200 mg daily, doses above 1.0 mL may be split into two injections at different sites to improve comfort.

Reconstitution Steps

  1. Draw 2.0 mL bacteriostatic water (0.9% benzyl alcohol) with a sterile syringe.
  2. Inject slowly down the vial wall to minimize foaming; avoid direct stream onto powder.
  3. Gently swirl or roll the vial until powder is fully dissolved (do not shake vigorously).
  4. Label vial with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 2–4 weeks; bacteriostatic water preservative inhibits microbial growth during multi-dose use[6].